Bayer HealthCare Animal Health Division has Fido and Bessie's wellness in mind. The company is part of the health care division of global chemical and pharmaceutical giant Bayer. The Animal Health Division manufactures anti-infectives, insecticides, parasiticides, sedatives, nutritional supplements, vaccines, and other pharmaceuticals for companion (dogs, cats, horses) and farm (cattle, pigs, poultry, bees) animals. Major products include flea and heartworm treatment Advantage and anti-infective Baytril. The division operates more than 50 branch locations worldwide and sells its products in some 120 countries.

Keryx Biopharmaceuticals, Inc. was founded in 1998 and is based in New York, New York. Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Its products under development include Zerenex, an oral iron-based compound is in Phase II clinical development for the treatment of hyperphosphatemia in patients with end-stage renal disease in the United States and Japan; and KRX-0401, an oral anti-cancer agent in Phase II clinical development that modulates Akt, and various other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation, and cell survival. Keryx Biopharmaceuticals has strategic alliances with AEterna Zentaris Inc.; Panion & BF Biotech, Inc.; Japan Tobacco Inc.; and Torii Pharmaceutical Co., Ltd. for the manufacture and commercialization of its products.

Agennix develops oral, topical, and other forms of cancer treatments. The company's primary candidate, Talactoferrin, is an oral therapy in the late stages of development that is targeted to treat non-small cell lung cancer, a common and slow-growing type of lung cancer. Its other clinical development-stage candidates include therapies to treat tumors and prostate cancer, as well as non-cancerous conditions such as sepsis and diabetic foot ulcers. Agennix, which has offices in Munich, Germany; Princeton, New Jersey; and Houston, Texas, was formed in 2009 from the merger of Germany-based GPC Biotech AG and US-based Agennix Inc.

Orion shines brightly over Scandinavia. At the heart of the health care group is Orion Pharma, one of Finland's largest drug makers. Orion Pharma manufactures prescription, generic, and OTC pharmaceuticals, as well as veterinary medicines. Its Fermion subsidiary manufactures active pharmaceutical ingredients (API) for use by Orion and other drug makers. Orion company's research is focused on developing treatments for central nervous system, cardiovascular, and urological disorders, as well as cancer. Orion Diagnostica develops and manufactures diagnostic tests to be used on site in physicians' offices.

IS Pharma, formerly known as Maelor, is a UK-based drug and medical device company focused on products for the hospital market; it sells directly in the UK and uses distributors elsewhere. Among its products are Volpex, Haemopressin, and ISOplex, all critical care products used in surgery; Mysoline, an oral treatment for epilepsy; and Cryogesic and Aloxi, two cancer drugs. Maelor outlicenses some products outside its core focus areas to other firms, including its OptiFlo catheter, which is distributed by C.R. Bard. Previously limited primarily to the UK market, the firm bought Swiss drug firm Specialty European Pharma International in 2008, giving it a wider presence in Europe and in North America.

Warner Chilcott plc company was founded in 1968 and is headquartered in Rockaway, New Jersey. Warner Chilcott PLC, formerly Warner Chilcott Limited, is a Bermuda-based specialty pharmaceutical company focused on the women’s healthcare and dermatology segments of the United States pharmaceutical market. It is an integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. Its operations are carried through its wholly-owned subsidiaries in the United States, Puerto Rico, the Republic of Ireland and Northern Ireland. The Companies franchises are comprised of complementary portfolios of established branded and development-stage products. In October 2009, the Company announced it completed the acquisition of The Procter & Gamble Company’s global branded prescription pharmaceutical business.

Actelion Ltd is a Swiss biopharmaceutical company with a global presence that focuses on the discovery, development and commercialization of treatments to serve unmet medical needs. Its products specialize in conditions related to the endothelium, the single layer of cells separating every blood vessel from the blood stream. The Company has three approved drugs on the market. Tracleer, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension, a chronic, life-threatening disorder that severely compromises the functions of the lungs and heart. The second product, Zavesca, was in-licensed from Oxford GlycoSciences. Zavesca is an approved oral treatment for type 1 Gaucher disease, a rare debilitating metabolic disorder. Ventavis, the third product, is an inhaled synthetic analogue of prostacyclin that produces potent pulmonary vasodilation and inhibits platelet aggregation, among other benefits.

Mirari Biosciences was founded in 2000 by CEO Mark Martin, who developed the MASC and Peplica technologies. Mirari Biosciences it working to cut down on the time its takes to test new drugs. The first of the company's two primary technologies is microwave-accelerated surface chemistry (MASC) which can speed up drug discovery tests, medical and veterinary diagnostics, and food and water testing by exposing test materials to low-heat microwaves. Its protein amplification technology (Peplica) replicates proteins which helps researchers locate and identify minute levels of proteins.

Monogram Biosciences, Inc. Diagnostics company operates in the growing field of personalized medicine, creating laboratory tests that help doctors tailor treatments for infectious disease and cancer patients based on the patients' genetic traits. Its PhenoSense and GenSeq tests determine patients' drug resistance to various classes of HIV drugs. It has also introduced its Trofile assay, which helps doctors choose patients who will be responsive to a new class of HIV drugs called CCR5 antagonists. Monogram markets its products to doctors and reference laboratories (for patient treatment) and to drug researchers (for clinical trials). The company was acquired by LabCorp in 2009.

Huntingdon Life Sciences Limited, a subsidiary of Life Sciences Research, is a leading contract research organization (CRO) that tests the safety of agrochemicals, foods, flavorings, industrial chemicals, pharmaceuticals and veterinary products. Huntingdon Life Sciences also provides drug development services for biotechnology and pharmaceutical companies, including Phase I-III testing, genetic toxicology assays, and microbiological activities.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.